CA-AQUA-LUNG
11.9.2019 00:27:02 CEST | Business Wire | Press release
Aqua Lung , the celebrated pioneer, designer, manufacturer and distributor of dive and watersports equipment for 75 years, has appointed Mr. Matthieu Bazil as its new CEO, effective immediately. Mr. Bazil will be based from the Aqua Lung Group offices in Carros, France.
Bazil takes the helm as Aqua Lung continues on a path of global leadership in developing and bringing to market the best in scuba, swim, snorkel, and recreational paddle sport products. Bazil, a passionate watersports enthusiast and scuba diver, comes to Aqua Lung after highly successful engagements at Fox Racing, Oxbow, Boardriders Inc. (with global leadership roles at both DC Shoes and Quiksilver), and key account management with adidas.
“I have worked in the sports industry all my life and have sought out brands that are authentic and credible in their space and leaders in their industry. Aqua Lung fits this definition perfectly, being the pioneer of scuba diving, and each brand of the portfolio being the most authentic and credible player in their segment,” said Mr. Bazil.
The Aqua Lung Group is fully committed to evolving and innovating the absolute best products to inspire every type of water exploration, led by scuba brands Aqua Lung and Apeks Diving. The Group is also heavily invested in the world of swimming, with Aqua Sphere and a longstanding partnership with Michael Phelps around the MP Brand swimming line for competitive swimmers and triathletes.
“We will rely most on the strength of our assets, whether it’s the best to ever get in the pool in Michael Phelps, or the first family of the Oceans with Philippe and Ashlan Cousteau -- combining these iconic personalities with our incredibly capable internal teams and brands, we will push forward with truly remarkable next-generation products built by our dedicated experts worldwide. There is much on the horizon for the Aqua Lung Group and it is my honor to be joining this talented team,” concluded Mr. Bazil.
About the Aqua Lung Group
Aqua Lung pioneered the creation of modern diving equipment in 1943 when Captain Jacques-Yves Cousteau teamed with Emile Gagnan to develop the first “aqua-lung” that made underwater exploration possible. Today, the brand continues to be the leading global designer and manufacturer of dive and water sports gear. With a deep commitment to quality, research and testing, Aqua Lung has revolutionized the scuba diving experience by setting industry standards for scuba equipment in technology, comfort, safety and design. The company’s rich history as an expert in the dive and water sports industry has led to the demand of Aqua Lung equipment for recreational, swim, technical and military applications in more than 100 countries around the world, under the brand names Aqua Lung, MP Michael Phelps, Aqua Sphere, Apeks, O.ME.R, U.S. Divers, and Stohlquist. For more information, visit www.AquaLung.com , http://www.Facebook.com/AquaLungDivers .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910006162/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom